These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23674341)

  • 1. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
    Cuckle H; Benn P; Pergament E
    Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
    Ohno M; Caughey A
    Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada.
    Okun N; Teitelbaum M; Huang T; Dewa CS; Hoch JS
    Prenat Diagn; 2014 Apr; 34(4):350-6. PubMed ID: 24395030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal screening costs at a large military treatment facility.
    Shiv E; Sale TJ; Simsiman A; Leininger WM; Lutgendorf MA
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1584-1587. PubMed ID: 27431854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for Implementing Cell-Free DNA Testing.
    Cuckle H
    Clin Lab Med; 2016 Jun; 36(2):213-26. PubMed ID: 27235907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quadruple test for Down syndrome screening in pregnant women of advanced maternal age.
    Kwon JY; Park IY; Kwon SM; Kim CJ; Shin JC
    Arch Gynecol Obstet; 2012 Mar; 285(3):629-33. PubMed ID: 21837420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis comparing two different strategies in advanced maternal age: Combined first-trimester screening and maternal blood cell-free DNA testing.
    Pan M; Huang LY; Zhen L; Li DZ
    Taiwan J Obstet Gynecol; 2018 Aug; 57(4):536-540. PubMed ID: 30122574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
    Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
    Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
    Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive chromosome test raises new questions in prenatal diagnosis about the significance of ultrasound and questions about new screening strategies.
    Tercanli S; Vial Y; Merz E
    Ultraschall Med; 2013 Oct; 34(5):417-20. PubMed ID: 24127381
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost analysis of Down syndrome screening in advanced maternal age.
    Hartnett J; Borgida AF; Benn PA; Feldman DM; DeRoche ME; Egan JF
    J Matern Fetal Neonatal Med; 2003 Feb; 13(2):80-4. PubMed ID: 12735407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome.
    Walker BS; Jackson BR; LaGrave D; Ashwood ER; Schmidt RL
    Prenat Diagn; 2015 May; 35(5):440-6. PubMed ID: 25273838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing.
    Heckerling PS; Verp MS
    Med Care; 1994 Aug; 32(8):863-80. PubMed ID: 8057700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost utility of prenatal diagnosis and the risk-based threshold.
    Harris RA; Washington AE; Nease RF; Kuppermann M
    Lancet; 2004 Jan; 363(9405):276-82. PubMed ID: 14751700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Cell-Free DNA Screening vs Direct Invasive Diagnosis on Miscarriage Rates in Women With Pregnancies at High Risk of Trisomy 21: A Randomized Clinical Trial.
    Malan V; Bussières L; Winer N; Jais JP; Baptiste A; Le Lorc'h M; Elie C; O'Gorman N; Fries N; Houfflin-Debarge V; Sentilhes L; Vekemans M; Ville Y; Salomon LJ;
    JAMA; 2018 Aug; 320(6):557-565. PubMed ID: 30120476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential and contingent prenatal screening for Down syndrome.
    Wald NJ; Rudnicka AR; Bestwick JP
    Prenat Diagn; 2006 Sep; 26(9):769-77. PubMed ID: 16821246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.